Paul Brennan

Sage Bionetworks

$1,504,570

Attributed

$6,018,281

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7.2M · FY2017–22

$10M$7.5M$5M$2.5M$0

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$13,235,817 · 2

By mechanism

U54$7,217,536 · 1

RF1$6,018,281 · 1

Top collaborators

Others in their field

Other Emerging Leaders on “Alzheimer&Apos”

Lance Allen Johnson · University Of Kentucky$7,508,882
Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
Jessica Brooke Langbaum · Banner Health$6,050,741
Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362

Research focus

Alzheimer&AposS DiseaseValidationProteinsMedicineBiologyProgramsDrug DiscoveryReagentComputer SimulationDesignBaseResearch PersonnelResourcesFundingGenesDrug DevelopmentAntibodiesDisease ProgressionOpen DataBiologicalParent ProjectNeurodegenerative DisordersPathway Interactions

Grant awards (6)

Open Drug Discovery Center for Alzheimer's Disease$7,217,536

U54 · FY2022 · AG

Validation of Antibody Reagents for 15 High Priority AMP-AD Targets$287,500

RF1 · FY2019 · AG

Expanding Target Enabling Packages for AMP-AD Target Validation to identify small molecule inhibitors that block protein-protein interactions in cells$252,472

RF1 · FY2019 · AG

Infrastructure to improve reliability of AMP-AD target hypotheses$1,885,852

RF1 · FY2018 · AG

Expanding AMP-AD Target Enabling Packages to identify small molecule inhibitors that block protein-protein interaction$202,186

RF1 · FY2018 · AG

Open systems for AMP-AD target enhancement$3,390,271

RF1 · FY2017 · AG